Halda Therapeutics appoints Christian Schade as President and CEO to advance novel cancer therapies

New Haven, CT, October 1, 2024 (Business Wire) -- Halda Therapeutics has appointed Christian Schade as President and CEO, enhancing its leadership as it develops its novel RIPTAC™ cancer therapies. Schade brings over two decades of experience in the biotechnology and pharmaceutical industries, focusing on clinical development and strategic transactions. Prior roles include Growth Partner at Flagship Pioneering, President and CEO at Aprea Therapeutics, CEO of Novira, CFO of Omthera Pharmaceuticals, and SVP and CFO at Medarex. Tim Shannon will continue as Chairman of the Board, ensuring stability during this leadership change.

Read full article here.